Drug Profile
Research programme: amyotrophic lateral sclerosis therapeutics - Iron Horse Therapeutics
Alternative Names: EPH receptor 4 inhibitors - Iron Horse Therapeutics; EphA4 inhibitors - Iron Horse Therapeutics; Ephrin type A receptor 4 inhibitors - Iron Horse TherapeuticsLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Sanford-Burnham Medical Research Institute
- Developer Iron Horse Therapeutics; Sanford Burnham Prebys Medical Discovery Institute
- Class Small molecules
- Mechanism of Action Eph family receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route) before August 2023
- 28 Dec 2019 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 09 Nov 2015 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)